Comparative analysis of the use of technetium-99m labeled recombinant target molecules at doses of 1000 and 2000 μg for radionuclide diagnostics of HER2-positive breast cancer. Voprosy onkologii, v. 68, n. 1, p. 60–65, 28 Feb.2022.